Literature DB >> 8676525

Inhibition of human immunodeficiency virus type 1 replication is enhanced by a combination of transdominant Tat and Rev proteins.

C Ulich1, D Harrich, P Estes, R B Gaynor.   

Abstract

Mutation of either of two critical human immunodeficiency virus type 1 (HIV-1) regulatory proteins, Tat and Rev, results in marked defects in viral replication. Thus, inhibition of the function of one or both of these proteins can significantly inhibit viral growth. In the present study, we constructed a novel transdominant Tat mutant protein and compared its efficiency in inhibiting HIV-1 replication with that of transdominant mutant Rev M10 when these proteins were stably expressed either alone or in combination in T-lymphocyte cell lines. The transdominant Tat mutant protein alone resulted in a modest inhibition of HIV replication, but it was able to enhance the ability of the M10 Rev mutant protein to inhibit HIV-1 replication. These results suggest a possible synergistic effect of these transdominant mutant proteins in inhibiting HIV-1 replication.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8676525      PMCID: PMC190435     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

1.  trans-dominant inhibition of human immunodeficiency virus type 1 Rev occurs through formation of inactive protein complexes.

Authors:  T J Hope; N P Klein; M E Elder; T G Parslow
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

2.  The trans-activator gene of HTLV-III is essential for virus replication.

Authors:  A G Fisher; M B Feinberg; S F Josephs; M E Harper; L M Marselle; G Reyes; M A Gonda; A Aldovini; C Debouk; R C Gallo
Journal:  Nature       Date:  1986 Mar 27-Apr 2       Impact factor: 49.962

3.  A second post-transcriptional trans-activator gene required for HTLV-III replication.

Authors:  J Sodroski; W C Goh; C Rosen; A Dayton; E Terwilliger; W Haseltine
Journal:  Nature       Date:  1986 May 22-28       Impact factor: 49.962

4.  The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA.

Authors:  M H Malim; J Hauber; S Y Le; J V Maizel; B R Cullen
Journal:  Nature       Date:  1989-03-16       Impact factor: 49.962

5.  Gene therapy. Intracellular immunization.

Authors:  D Baltimore
Journal:  Nature       Date:  1988-09-29       Impact factor: 49.962

6.  Site-directed mutagenesis of two trans-regulatory genes (tat-III,trs) of HIV-1.

Authors:  M R Sadaie; T Benter; F Wong-Staal
Journal:  Science       Date:  1988-02-19       Impact factor: 47.728

7.  HTLV-III expression and production involve complex regulation at the levels of splicing and translation of viral RNA.

Authors:  M B Feinberg; R F Jarrett; A Aldovini; R C Gallo; F Wong-Staal
Journal:  Cell       Date:  1986-09-12       Impact factor: 41.582

8.  Structural and functional characterization of human immunodeficiency virus tat protein.

Authors:  S Ruben; A Perkins; R Purcell; K Joung; R Sia; R Burghoff; W A Haseltine; C A Rosen
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

9.  Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS.

Authors:  M Popovic; M G Sarngadharan; E Read; R C Gallo
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

10.  Functional domains required for tat-induced transcriptional activation of the HIV-1 long terminal repeat.

Authors:  J A Garcia; D Harrich; L Pearson; R Mitsuyasu; R B Gaynor
Journal:  EMBO J       Date:  1988-10       Impact factor: 11.598

View more
  10 in total

1.  A mutant tat protein inhibits HIV-1 reverse transcription by targeting the reverse transcription complex.

Authors:  Min-Hsuan Lin; Ann Apolloni; Vincent Cutillas; Haran Sivakumaran; Sally Martin; Dongsheng Li; Ting Wei; Rui Wang; Hongping Jin; Kirsten Spann; David Harrich
Journal:  J Virol       Date:  2015-02-11       Impact factor: 5.103

2.  A mutant Tat protein provides strong protection from HIV-1 infection in human CD4+ T cells.

Authors:  Ann Apolloni; Min-Husan Lin; Haran Sivakumaran; Dongsheng Li; Michael H R Kershaw; David Harrich
Journal:  Hum Gene Ther       Date:  2013-03-01       Impact factor: 5.695

3.  Differential Effects of Strategies to Improve the Transduction Efficiency of Lentiviral Vector that Conveys an Anti-HIV Protein, Nullbasic, in Human T Cells.

Authors:  Lina Rustanti; Hongping Jin; Dongsheng Li; Mary Lor; Haran Sivakumaran; David Harrich
Journal:  Virol Sin       Date:  2018-03-14       Impact factor: 4.327

4.  Functional domains of Tat required for efficient human immunodeficiency virus type 1 reverse transcription.

Authors:  C Ulich; A Dunne; E Parry; C W Hooker; R B Gaynor; D Harrich
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

5.  Human immunodeficiency virus type 1 protease regulation of tat activity is essential for efficient reverse transcription and replication.

Authors:  Ann Apolloni; C William Hooker; Johnson Mak; David Harrich
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

6.  Impact of Tat Genetic Variation on HIV-1 Disease.

Authors:  Luna Li; Satinder Dahiya; Sandhya Kortagere; Benjamas Aiamkitsumrit; David Cunningham; Vanessa Pirrone; Michael R Nonnemacher; Brian Wigdahl
Journal:  Adv Virol       Date:  2012-07-30

Review 7.  Tat-Based Therapies as an Adjuvant for an HIV-1 Functional Cure.

Authors:  Hongping Jin; Dongsheng Li; Min-Hsuan Lin; Li Li; David Harrich
Journal:  Viruses       Date:  2020-04-08       Impact factor: 5.048

8.  Potent inhibition of HIV-1 replication by a Tat mutant.

Authors:  Luke W Meredith; Haran Sivakumaran; Lee Major; Andreas Suhrbier; David Harrich
Journal:  PLoS One       Date:  2009-11-10       Impact factor: 3.240

9.  Nullbasic, a potent anti-HIV tat mutant, induces CRM1-dependent disruption of HIV rev trafficking.

Authors:  Min-Hsuan Lin; Haran Sivakumaran; Ann Apolloni; Ting Wei; David A Jans; David Harrich
Journal:  PLoS One       Date:  2012-12-10       Impact factor: 3.240

10.  Shutdown of HIV-1 Transcription in T Cells by Nullbasic, a Mutant Tat Protein.

Authors:  Hongping Jin; Dongsheng Li; Haran Sivakumaran; Mary Lor; Lina Rustanti; Nicole Cloonan; Shivangi Wani; David Harrich
Journal:  MBio       Date:  2016-07-05       Impact factor: 7.867

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.